跳至主要内容
临床试验/NCT00574223
NCT00574223已完成2 期

Double-Blind, Placebo-Controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immunotherapy Combining Allergen With CYT003-QbG10 (CYT005-AllQbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis Due to House Dust Mite Allergy

Cytos Biotechnology AG1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
100
试验地点
1
主要终点
Conjunctival provocation test with allergen and rhinoconjunctivitis symptoms in daily life

研究概览

简要总结

The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mild to moderate perennial allergic rhinoconjunctivits due to hypersensitization towards house dust mite allergens

排除标准

  • Clinically relevant other allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments
  • Use of any concomitant medication that could affect the patient's study treatment response or assessment results

研究组 & 干预措施

Arm 1

Experimental

干预措施: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10) (Drug)

Arm 2

Placebo Comparator

干预措施: House dust mite allergen extract in combination with CYT003-QbG10-placebo (Drug)

结局指标

主要结局

Conjunctival provocation test with allergen and rhinoconjunctivitis symptoms in daily life

时间窗: about 1.5 hours on 4 occasions over 1 year

次要结局

  • Safety and tolerability of the study treatment by collection of adverse events(about 30 min. at each visit)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

A Study to Investigate an Immunomodulatory Therapy... | 临床试验